Advertisement

Journal of Neural Transmission

, Volume 122, Issue 1, pp 5–28 | Cite as

Clinical applications of CYP genotyping in psychiatry

  • Edoardo SpinaEmail author
  • Jose de Leon
Psychiatry and Preclinical Psychiatric Studies - Review Article

Abstract

A critical review of the limited available evidence and the authors’ experience and judgment are used to summarize the role of cytochrome P450 (CYP) genetic variants in the pharmacokinetics of and clinical response to psychotropic medications. CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 genetic polymorphisms and their contributions to the metabolism of psychotropic drugs are reviewed. CYP1A2, CYP2B6 and CYP3A4 genotyping have limited current clinical utility. CYP2C9 genotyping has no utility in psychiatry. Psychiatrists should master tricyclic antidepressant (TCA) prescription, and if they use TCAs, they should have expertise in CYP2D6 and CYP2C19 genotyping and in TCA therapeutic drug monitoring (TDM) to safely dose TCAs. Practice guidelines recommend dose changes, TDM or alternate drugs for (1) CYP2C19 ultrarapid metabolizers (UM) taking citalopram or escitalopram; (2) CYP2C19 poor metabolizers (PMs) taking sertraline; (3) CYP2D6 PMs taking venlafaxine, aripiprazole, haloperidol, risperidone or zuclopenthixol; and (4) CYP2D6 UMs taking venlafaxine, aripiprazole, haloperidol, risperidone, zuclopenthixol or atomoxetine. According to the prescribing information, CYP2D6 PMs should receive 75 % of the average long-acting aripiprazole dose and pimozide doses >4 mg/day should not be prescribed without CYP2D6 genotyping. In a situation of limited evidence, there is need to use the available pharmacological mechanistic information for better personalizing treatment in psychiatry. This is best done by combining CYP genotyping with TDM. Clozapine and risperidone concentration-to-dose ratios are provided as two examples of this approach of how to integrate CYP genotyping and TDM in psychiatry. New studies are needed to verify that CYP2C19 PM genotyping may have potential to identify clozapine PMs and explain the lower clozapine metabolic capacity in East Asians.

Keywords

Cytochrome P450 enzyme system Genetic testing Pharmacogenetics Practice guideline Psychopharmacology Psychotropic drug 

Notes

Acknowledgments

The authors acknowledge Lorraine Maw, M.A., and Margaret T. Boden, R.N., M.L.T., at the Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA, who helped in editing the article.

Conflict of interest

No commercial organizations had any role in the writing of this paper for publication. In the past few years, Dr. Spina has participated in speakers/advisory boards and lectures supported by AstraZeneca, Bristol-Myers, Eli Lilly & Co, Janssen Pharmaceuticals, Lundbeck and Pfizer. Dr. de Leon personally develops his presentations for lecturing, has never lectured using any pharmaceutical or pharmacogenetic company presentations and has never been a consultant for pharmacogenetic or pharmaceutical companies. In the past, Dr. de Leon received researcher-initiated grants from Eli Lilly (one ended in 2003 and the other, as co-investigator, ended in 2007); from Roche Molecular Systems, Inc. (ended in 2007); and, in a collaboration with Genomas, Inc., from the NIH Small Business Innovation Research program (ended in 2010). He has been on the advisory boards of Bristol-Myers Squibb (2003/2004) and AstraZeneca (2003). Roche Molecular Systems supported one of his educational presentations, which was published in a peer-reviewed journal (2005). His lectures were supported once by Sandoz (1997), twice by Lundbeck (1999 and 1999), twice by Pfizer (2001 and 2001), three times by Eli Lilly (2003, 2006 and 2006), twice by Janssen (2000 and 2006), once by Bristol-Myers Squibb (2006) and seven times by Roche Molecular Systems, Inc. (once in 2005 and six times in 2006).

References

  1. Alessandrini M, Asfaha S, Dodgen TM, Warnich L, Pepper MS (2013) Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 45:253–275PubMedGoogle Scholar
  2. Benowitz NL, Zhu AZX, Tyndale RF et al (2013) Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenetics Genomics 23:135–141PubMedCentralPubMedGoogle Scholar
  3. Berecz R, de la Rubia A, Dorado P et al (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59:45–50PubMedGoogle Scholar
  4. Bertilsson L (2007) Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 82:606–609PubMedGoogle Scholar
  5. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122PubMedCentralPubMedGoogle Scholar
  6. Bork JA, Rogers T, Wedlund PJ, de Leon J (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60:469–476PubMedGoogle Scholar
  7. Brosen K, Klysner R, Gram LF et al (1986) Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30:679–684PubMedGoogle Scholar
  8. Bunten H, Liang WJ, Pounder D et al (2011) CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16:142–144PubMedGoogle Scholar
  9. Cabaleiro T, López-Rodríguez R, Ochoa D et al (2013) Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol 28:205–214PubMedGoogle Scholar
  10. Carlsson B, Olsson G, Reis M et al (2001) Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit 23:658–664PubMedGoogle Scholar
  11. Carrillo JA, Dahl ML, Svensson JO et al (1996) Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183–190PubMedGoogle Scholar
  12. Carrillo JA, Herraiz AG, Ramos SI et al (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23:119–127PubMedGoogle Scholar
  13. Chang WH, Lin SK, Lane HY (1997) Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 96:599–605PubMedGoogle Scholar
  14. Charlier C, Broly F, Lhermitte M et al (2003) Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 25:738–742PubMedGoogle Scholar
  15. Chou WH, Yan FX, de Leon J et al (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246–251PubMedGoogle Scholar
  16. Cozza KL, Armstrong SC, Oesterheld JR (2003) Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-glycoproteins, 2nd edn. American Psychiatric Association, Washington, DCGoogle Scholar
  17. Crettol S, Déglon JJ, Besson J et al (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604PubMedGoogle Scholar
  18. Crettol S, de Leon J, Hiemke C, Eap CB (2014) Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 95:254–257PubMedGoogle Scholar
  19. Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453–470PubMedGoogle Scholar
  20. Dahl ML, Bertilsson L, Nordin C (1996) Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 123:315–319PubMedGoogle Scholar
  21. Dahl-Puustinen ML, Liden A, Alm C et al (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46:78–81PubMedGoogle Scholar
  22. Dai D, Tang J, Rose R, Hodgson E et al (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825–831PubMedGoogle Scholar
  23. Dalen P, Dahl ML, Ruiz ML et al (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444–452PubMedGoogle Scholar
  24. de Leon J (2006) AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 6:277–286PubMedGoogle Scholar
  25. de Leon J (2007) The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 27:241–245PubMedGoogle Scholar
  26. de Leon J (2008) The potential of genotyping. Science 321:769PubMedGoogle Scholar
  27. de Leon J (2009) The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59:81–89PubMedGoogle Scholar
  28. de Leon J (2012) Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 32:153–164PubMedGoogle Scholar
  29. de Leon J (2014a) False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: focus on epilepsy. J Clin Psychopharmacol 34:177–183PubMedGoogle Scholar
  30. de Leon J (2014b) False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder. J Clin Psychopharmacol 34:291–296PubMedGoogle Scholar
  31. de Leon J, Armstrong SC, Cozza KL (2006a) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47:75–85PubMedGoogle Scholar
  32. de Leon J, Greenlee B, Barber J et al (2009a) Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil 30:613–669PubMedGoogle Scholar
  33. de Leon J, Sandson NB, Cozza KL (2008) A preliminary attempt to personalize risperidone dosing using drug–drug interactions and genetics: part II. Psychosomatics 49:347–361PubMedGoogle Scholar
  34. de Leon J, Santoro V, D’Arrigo C, Spina E (2012) Interactions between antiepileptics and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 8:311–334Google Scholar
  35. de Leon J, Spina E, Diaz FJ (2013) Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 35:30–47PubMedCentralPubMedGoogle Scholar
  36. de Leon J, Spina E, Diaz FJ (2009b) Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol 29:201–205PubMedGoogle Scholar
  37. de Leon J, Susce MT, Johnson M et al (2009c) DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 14:19–34PubMedGoogle Scholar
  38. de Leon J, Susce MT, Murray-Carmichael E (2006b) The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 10:135–151PubMedGoogle Scholar
  39. de Leon J, Susce MT, Pan RM et al (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15–27PubMedGoogle Scholar
  40. de Leon J, Susce MT, Pan RM et al (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93–102PubMedGoogle Scholar
  41. de Leon J, Wynn G, Sandson NB (2010) The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51:80–88PubMedGoogle Scholar
  42. Desta Z, Zhao X, Shin JG et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958PubMedGoogle Scholar
  43. de Vos A, van der Weide J, Loovers HM (2011) Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 11:359–367PubMedGoogle Scholar
  44. Drögemöller BI, Wright GE, Niehaus DJ, Emsley R, Warnich L (2013) Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment. Pharmacogenetics Genomics 23:666–674PubMedGoogle Scholar
  45. Drögemöller BI, Wright GE, Warnich L (2014) Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opin Drug Metab Toxicol 10:873–884PubMedGoogle Scholar
  46. Eap CB, Bender S, Jaquenoud SE et al (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 24:214–219PubMedGoogle Scholar
  47. Eap CB, Bondolfi G, Zullino D et al (2001) Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21:330–334PubMedGoogle Scholar
  48. Eap CB, Crettol S, Rougier JS et al (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719–728PubMedGoogle Scholar
  49. Eap CB, Lessard E, Baumann P et al (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13:39–47PubMedGoogle Scholar
  50. Eiermann B, Engel G, Johansson I et al (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439–446PubMedCentralPubMedGoogle Scholar
  51. Ereshefsky L (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(Suppl 11):12–25PubMedGoogle Scholar
  52. Fang J, McKay G, Song J et al (2001) In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos 29:1638–1643PubMedGoogle Scholar
  53. Fric M, Pfuhlmann B, Laux G et al (2008) The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 41:151–155PubMedGoogle Scholar
  54. Fudio S, Borobia AM, Pinana E et al (2010) Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 626:200–204PubMedGoogle Scholar
  55. Fukuda T, Nishida Y, Zhou Q et al (2000) The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56:175–180PubMedGoogle Scholar
  56. Gaohua L, Abduljalil K, Jamei M et al (2012) A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol 74:873–885PubMedCentralPubMedGoogle Scholar
  57. Gerstenberg G, Aoshima T, Fukasawa T et al (2003) Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 25:463–468PubMedGoogle Scholar
  58. Grossman I, Sullivan PF, Walley N et al (2008) Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 10:720–729PubMedCentralPubMedGoogle Scholar
  59. Hägg S, Spigset O, Lakso HA, Dahlqvist R (2001) Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 57:493–497PubMedGoogle Scholar
  60. Hesse LM, Venkatakrishnan K, Court MH et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183PubMedGoogle Scholar
  61. Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402–408PubMedCentralPubMedGoogle Scholar
  62. Hiemke C, Baumann P, Bergemann N et al (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195–235Google Scholar
  63. Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 212:241–265PubMedGoogle Scholar
  64. Hiemke C, Shams M (2013) Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 10:46–53PubMedGoogle Scholar
  65. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphism on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526PubMedGoogle Scholar
  66. Inomata S, Nagashima A, Itagaki F et al (2005) CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 78:647–655PubMedGoogle Scholar
  67. Jan MW, ZumBrunnen TL, Kazmi YR et al (2002) Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabol Drug Interact 19:1–11PubMedGoogle Scholar
  68. Jaquenoud Sirot E, Knezevic B, Morena GP (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319–326PubMedGoogle Scholar
  69. Jerling M, Dahl ML, Aberg-Wistedt A et al (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 59:423–428PubMedGoogle Scholar
  70. Jiang ZP, Shu Y, Chen XP et al (2002) The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J Clin Pharmacol 58:109–113PubMedGoogle Scholar
  71. Jin Y, Pollock BG, Frank E et al (2010) Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 50:62–72PubMedCentralPubMedGoogle Scholar
  72. Johnson M, Markham-Abedi C, Susce MT et al (2006) A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr 11:757–760PubMedGoogle Scholar
  73. Katoh Y, Uchida S, Kawai M et al (2010) Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Bio Pharm Bull 33:285–288Google Scholar
  74. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59:803–807PubMedGoogle Scholar
  75. Kirchheiner J, Brosen K, Dahl ML et al (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation specific dosages. Acta Psychiatr Scand 104:173–192PubMedGoogle Scholar
  76. Kirchheiner J, Klein C, Meineke I et al (2003) Bupropion and 4-OH bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619–626PubMedGoogle Scholar
  77. Kirchheiner J, Nickchen K, Bauer M et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473PubMedGoogle Scholar
  78. Kohnke MD, Griese EU, Stosser D et al (2002) Cytochrome P4502D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35:116–118PubMedGoogle Scholar
  79. Kootstra-Ros JE, Smallegoor W, van der WJ (2005) The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 42:216–219Google Scholar
  80. Koyama E, Tanaka T, Chiba K et al (1996) Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 16:286–293PubMedGoogle Scholar
  81. Laika B, Leucht S, Heres S et al (2010) Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 10:20–29PubMedGoogle Scholar
  82. Lantz RJ, Gillespie TA, Rash TJ et al (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31:1142–1150PubMedGoogle Scholar
  83. Lind AB, Reis M, Bengtsson F et al (2009) Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 48:63–70PubMedGoogle Scholar
  84. Linnet K (2002) Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17:233–238PubMedGoogle Scholar
  85. Linnet K, Wiborg O (1996a) Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 18:629–634PubMedGoogle Scholar
  86. Linnet K, Wiborg O (1996b) Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 60:41–47PubMedGoogle Scholar
  87. Liu ZQ, Cheng ZN, Huang SL et al (2001) Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 52:96–99PubMedCentralPubMedGoogle Scholar
  88. Llerena A, Alm C, Dahl ML et al (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:92–97PubMedGoogle Scholar
  89. Llerena A, Berecz R, Dorado P, de la Rubia A (2004a) QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 18:189–193PubMedGoogle Scholar
  90. Llerena A, Dorado P, Berecz R et al (2004b) Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 59:869–873PubMedGoogle Scholar
  91. Martis S, Mey H, Vijzelar R et al (2013) Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 13:558–566PubMedGoogle Scholar
  92. Matchar DB, Thakur ME, Grossman I et al (2006) Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Agency for Healthcare Research and Quality Publication No. 07-E002. Rockville. http://archive.ahrq.gov/downloads/pub/evidence/pdf/cyp450/cyp450.pdf. Accessed 23 June 2014
  93. McAllister-Williams RH, Baldwin DS, Haddad PM et al (2010) The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 25:95–102PubMedGoogle Scholar
  94. Melkersson KI, Scordo MG, Gunes A, Dahl ML (2007) Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 68:697–704PubMedGoogle Scholar
  95. Meyer UA (2004) Pharmacogenetics—five decades of therapeutic lessons from genetic diversity. Nat Rev 5:869–876Google Scholar
  96. Mihara K, Suzuki A, Kondo T et al (1999) Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 65:291–294PubMedGoogle Scholar
  97. Mihara K, Kondo T, Suzuki A et al (2001) Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients. Pharmacol Toxicol 88:267–270PubMedGoogle Scholar
  98. Morinobu S, Tanaka T, Kawakatsu S et al (1997) Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosi 51:253–257Google Scholar
  99. Murayama N, Soyama A, Saito Y et al (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308:300–306PubMedGoogle Scholar
  100. Nelson DR (2009) The cytochrome p450 homepage. Hum Genomics 4:59–65PubMedCentralPubMedGoogle Scholar
  101. Nichols AI, Lobello K, Guico-Pabia CJ et al (2009) Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 29:383–386PubMedGoogle Scholar
  102. Noehr-Jensen L, Zwisler ST, Larsen F et al (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 65:887–894PubMedGoogle Scholar
  103. Nozawa M, Ohnuma T, Matsubara Y et al (2008) The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 30(1):35–40PubMedGoogle Scholar
  104. Ostad Haji E, Hiemke C, Pfuhlmann B (2012) Therapeutic drug monitoring for antidepressant drug treatment. Curr Pharm Des 18:5818–5827PubMedGoogle Scholar
  105. Otsuka America Pharmaceutical, Inc. (2013) Abilify maintena-aripiprazole. Highlights of prescribing information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6#nlm34068-7. Accessed 28 June 2014
  106. Ozdemir V, Bertilsson L, Miura J et al (2007) CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenetics Genomics 17:339–347PubMedGoogle Scholar
  107. Ozdemir V, Kalow W, Okey AB et al (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C → A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21:603–607PubMedGoogle Scholar
  108. Ozdemir V, Kalow W, Tang BK et al (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–388PubMedGoogle Scholar
  109. Parker G, Fink M, Shorter E, Taylor MA et al (2010) Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry 167:745–747PubMedCentralPubMedGoogle Scholar
  110. Pavanello S, Pulliero A, Lupi S et al (2005) Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587:59–66PubMedGoogle Scholar
  111. Porcelli S, Fabbri C, Spina E et al (2011) Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Exp Opin Drug Metab Toxicol 7:1101–1115Google Scholar
  112. Preskorn SH (1989) Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J Clin Psychiatry 50(Suppl):34–42. (Discussion 43–46)Google Scholar
  113. Preskorn SH, Kane CP, Lobello K et al (2013) Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74:614–621PubMedGoogle Scholar
  114. Puranik YG, Birnbaum AK, Marino SE et al (2013) Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14:35–45PubMedCentralPubMedGoogle Scholar
  115. Rau T, Wohlleben G, Wuttke H et al (2004) CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. Clin Pharmacol Ther 75:386–393PubMedGoogle Scholar
  116. Ravyn D, Ravyn V, Lowney R, Nasrallah HA (2013) CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 149:1–14PubMedGoogle Scholar
  117. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448PubMedGoogle Scholar
  118. Ring BJ, Catlow J, Lindsay TJ et al (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658–666PubMedGoogle Scholar
  119. Rogers HL, Bhattaram A, Zineh I et al (2012) CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the US Food and Drug Administration’s new dosing recommendations. J Clin Psychiatry 73:1187–1190PubMedGoogle Scholar
  120. Roh HK, Kim CE, Chung WG et al (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57:671–675PubMedGoogle Scholar
  121. Rudberg I, Mohebi B, Hermann M et al (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322–327PubMedGoogle Scholar
  122. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449PubMedCentralPubMedGoogle Scholar
  123. Samer CF, Lorenzini KI, Rollason V et al (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17:165–184PubMedCentralPubMedGoogle Scholar
  124. Sawamura K, Suzuki Y, Someya T (2004) Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60:553–557PubMedGoogle Scholar
  125. Schenk PW, van Vliet M, Mathot RA et al (2010) The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J 10:3229–3225Google Scholar
  126. Scordo MG, Spina E (2002) Cytochrome P450 polymorphism and response to antipsychotic therapy. Pharmacogenomics 3:201–218PubMedGoogle Scholar
  127. Scordo MG, Spina E, Dahl ML et al (2005) Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 97:296–301PubMedGoogle Scholar
  128. Scordo MG, Spina E, Facciola G et al (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147:300–305PubMedGoogle Scholar
  129. Scott SA, Sangkuhl K, Gardner EE et al (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328–332PubMedCentralPubMedGoogle Scholar
  130. Sheffield LJ, Phillimore HE (2009) Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 30:55–65PubMedCentralPubMedGoogle Scholar
  131. Shen H, He MM, Liu H et al (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292–1300PubMedGoogle Scholar
  132. Shimada T, Yamazaki H, Mimura M et al (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423PubMedGoogle Scholar
  133. Shimoda K, Someya T, Yokono A et al (2002) The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 22:371–378PubMedGoogle Scholar
  134. Shirley KL, Hon YY, Penzak SR (2003) Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 28:961–966PubMedGoogle Scholar
  135. Sistonen J, Sajantila A, Lao O et al (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17:93–101Google Scholar
  136. Söderberg MM, Dahl ML (2013) Pharmacogenetics of olanzapine metabolism. Pharmacogenomics 14:1319–1336PubMedGoogle Scholar
  137. Someya T, Shimoda K, Suzuki Y (2003) Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 28:1501–1505PubMedGoogle Scholar
  138. Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4–22PubMedGoogle Scholar
  139. Spina E, de Leon J (2014) Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 10:721–746Google Scholar
  140. Spina E, Gitto C, Avenoso A et al (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51:395–398PubMedGoogle Scholar
  141. Spina E, Santoro V, D’Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206–1227PubMedGoogle Scholar
  142. Steimer W, Zopf K, Von Amelunxen S et al (2004) Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50:1623–1633PubMedGoogle Scholar
  143. Stormer E, von Moltke LL, Shader RI et al (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168–1175PubMedGoogle Scholar
  144. Strom CM, Goos D, Crossley B et al (2012) Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med 14:95–100PubMedGoogle Scholar
  145. Suzuki A, Otani K, Mihara K et al (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7:415–418PubMedGoogle Scholar
  146. Suzuki Y, Sugai T, Fukui N et al (2011) CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 25:908–914PubMedGoogle Scholar
  147. Swen JJ, Nijenhuis M, de Boer A et al (2011) Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 89:662–673PubMedGoogle Scholar
  148. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2014) The human Cytochrome P450 (CYP) allele nomenclature database. http://www.cypalleles.ki.se/. Accessed 11 Aug 2014
  149. Thieme D, Rolf B, Sachs H et al (2008) Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 122:149–155PubMedGoogle Scholar
  150. Tiwari AK, Souza RP, Müller DJ (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm 116:667–677PubMedGoogle Scholar
  151. Tod M, Goutelle S, Clavel-Grabit F et al (2011) Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet 50:519–530PubMedGoogle Scholar
  152. Tsai MH, Lin KM, Hsiao MC et al (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11:537–546PubMedGoogle Scholar
  153. Ueda M, Hirokane G, Morita S et al (2006) The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 30:486–491PubMedGoogle Scholar
  154. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE (2005) Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 27:478–483PubMedGoogle Scholar
  155. van der Weide K, van der Weide J (2014) The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol 34:256–260PubMedGoogle Scholar
  156. Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202–208PubMedGoogle Scholar
  157. Wang JH, Liu ZQ, Wang W et al (2001) Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70:42–47PubMedGoogle Scholar
  158. Watanabe J, Suzuki Y, Fukui N et al (2008) Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Ther Drug Monit 30:705–708PubMedGoogle Scholar
  159. Whyte EM, Romkes M, Mulsant BH et al (2006) CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 21:542–549PubMedGoogle Scholar
  160. Wong WB, Carlson JJ, Thariani R et al (2010) Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28:1001–1013PubMedGoogle Scholar
  161. Yin OQ, Wing YK, Cheung Y et al (2006) Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 26:367–372PubMedGoogle Scholar
  162. Yokono A, Morita S, Someya T et al (2001) The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 21:549–555PubMedGoogle Scholar
  163. Yu BN, Chen GL, He N et al (2003) Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 31:1255–1259PubMedGoogle Scholar
  164. Yu KS, Yim DS, Cho JY et al (2001) Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266–273PubMedGoogle Scholar
  165. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141PubMedGoogle Scholar
  166. Zhou SF (2009a) Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part I. Clin Pharmacokinet 48:689–723Google Scholar
  167. Zhou SF (2009b) Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part II. Clin Pharmacokinet 48:761–804PubMedGoogle Scholar
  168. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295PubMedGoogle Scholar
  169. Zhou SF, Zhou ZW, Huang M (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165–188PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  1. 1.Department of Clinical and Experimental MedicineUniversity of Messina, Policlinico UniversitarioMessinaItaly
  2. 2.University of Kentucky Mental Health Research Center at Eastern State HospitalLexingtonUSA
  3. 3.Psychiatry and Neurosciences Research Group (CTS-549), Institute of NeurosciencesUniversity of GranadaGranadaSpain
  4. 4.Biomedical Research Centre in Mental Health Net (CIBERSAM)Santiago Apóstol Hospital, University of the Basque CountryVitoriaSpain

Personalised recommendations